As of Tuesday, Verve Therapeutics Inc.’s (NASDAQ:VERV) stock closed at $22.49, down from $22.60 the previous day. While Verve Therapeutics Inc. has underperformed by -0.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VERV fell by -30.84%, with highs and lows ranging from $43.00 to $10.70, whereas the simple moving average fell by -8.31% in the last 200 days.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
On December 15, 2022, Goldman started tracking Verve Therapeutics Inc. (NASDAQ: VERV) recommending Sell. A report published by Credit Suisse on October 06, 2022, Initiated its previous ‘Neutral’ rating for VERV. Stifel also Upgraded VERV shares as ‘Buy’, setting a target price of $56 on the company’s shares in a report dated August 25, 2022. BMO Capital Markets Initiated an Outperform rating on June 17, 2022, and assigned a price target of $48. RBC Capital Mkts initiated its ‘Outperform’ rating for VERV, as published in its report on February 18, 2022. Stifel’s report from September 24, 2021 suggests a price prediction of $58 for VERV shares, giving the stock a ‘Hold’ rating. William Blair also rated the stock as ‘Outperform’.
Analysis of Verve Therapeutics Inc. (VERV)
One of the most important indicators of Verve Therapeutics Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -38.50% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.40, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and VERV is recording 977.18K average volume. On a monthly basis, the volatility of the stock is set at 6.90%, whereas on a weekly basis, it is put at 7.39%, with a loss of -3.31% over the past seven days. Furthermore, long-term investors anticipate a median target price of $44.78, showing growth from the present price of $22.49, which can serve as yet another indication of whether VERV is worth investing in or should be passed over.
How Do You Analyze Verve Therapeutics Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.00%. This can enable you to see the extent to which executives own the company’s stock.
Are institutional investors increasing their holdings in VERV shares?
The recent increase in stakes in VERV appears to be a result of several institutional investors and hedge funds increasing their positions. Fidelity Management & Research Co’s position in VERV has increased by 38.50% in the first quarter. The company now owns 5,902,017 shares of the stock, with a value of $114.2 million, following the purchase of 1,640,589 additional shares during the last quarter. The Vanguard Group, Inc. made another increased to its shares in VERV during the first quarter, upping its stake by 55.96%. During the last quarter, the company picked up 1,288,681 additional shares for a total stake of worth $69.5 million, bringing number of shares owned by the company to 3,591,697.
During the first quarter, ARK Investment Management LLC added a 1,359,735 position in VERV. Casdin Capital LLC purchased an additional 40000.0 shares in the last quarter, increasing its holdings by 1.27%, now holding 3.18 million shares worth $61.5 million. At the end of the first quarter, BlackRock Fund Advisors increased its VERV holdings by 34.60% and now holds 2.96 million VERV shares valued at $57.18 million with the added 0.76 million shares during the period.
